

Different Approaches

Organ system vs Organisms

- IE: what bacteria live where in the body?
- Skin vs GU Tract vs Oral Cavity all prone to different bugs.

Resources

- IDSA Guidelines
 - o https://www.idsociety.org/PracticeGuidelines/
- UK Antibiogram

Staphylococcus Staphylococcus Staphylococcus Staphylococcus

• ID Pharmacist

🐨 CareWeb - Clinician Deskt 🗙 🕂			- 🗆 X
• www.hosp.uky.edu/careweb/r	carehome.asp?PageName=General&Section=	C Q Search	☆ 白 ♣ ★ ♥ Ξ
HealthCar	re UK Resources -		CareWeb
STAR Program	limited to break/fix, emergency, and standard ch		ED Downtime Tool -
	to changes should be lifted following application information about changes and new functionalit		Chandler ED Downtime Tool - GS
Report a Breach	Clint Lush at 323-4462 if you have any questions		Equipment Resources
Report an Incident	chine cuan at 323-4402 in you have any questions		Health Manager
Sustainability	7/13/2017 - 27th Annual Nursing Re	search Papers Day	Kronos Pilot Group Link
			Nursing Staff
OVIHD - Quality	UK HealthCare Nursing Service in collaboration		Order Sets/Protocols
Quality and Patient Safety	Annual Nursing Research Papers Day - "Bringing Nursing Research"	the science to Life: innovations in	PageCenterX
Continuous Readiness			PatientWorks
Workplace Safety	Keynote Speaker:		SCM Resources
	Gail Stern, MSN, PMHCNS-BC		Staff Manager Info
Patient Experience	Administrator, Department of Psychiatry		Staff Manager Web
Infection Prevention	Lehigh Valley Hospital & Health Network		Login
Leadership	Bethlehem, PA		Transport Tracking XT
	Topic:		Patient Links
Physicians	The Evolution of Behavioral Health Integration: N	lew Roles in Nursing	ED Advanced Nursing Protocols
Nurses	Date:		Patient Diet Menus
Rehab	Friday, November 10, 2017		Patient Education
Pharmacy			Clinician Links
	Location:		Antibiograms
Perioperative Services	Hilton Downtown		Apheresis Request
Respiratory	369 West Vine Street, Lexington, KY 40507		Protocol Behavioral Standards
Information Technology	Conference Registration: http://www.ukconce.or	g/default.aspx	Chart Components
	2017 Abstract application: Click here		Order List
PPD		Read more	Chemo & Hazardous
Clinical Engineering			Med Database
Lab	7/9/2017 - SCM 16.3 Upgrade: New	Functionality!	Clinical Laboratory Clinical Practice
UK HealthCare	The SCM 16.3 Upgrade on July 9th, will bring ne	w functionality including a new Discharge	Guidelines
	Tab and Discharge orders that will optimize the		Clostridium difficile

Chandler Emergency Department
Chandler Medical Center
Good Samaritan
Kentucky Children's Hospital
Markey Cancer Center
CVICU
MICU
NSICU
PICU-NICU
SICU

		Cur						eptibi)						
					De	velop	ed Da	ate: Fe	ebrua	ry 15,	2018			-	-						
						Bet	ta-lacta	ms					Amin	oglyco	sides	FQ		Other		Urin	ary
Gram-Negative Organism	Number of isolates	Ampicillin	Amipcillin-sulbactam	Aztreonam	Ceftazidime	Ceftriaxone	Cefepime	Cefoxitin	Cefazolin	Ertapenem	Meropenem	Piperacillin-tazobactam	Amikacin	Gentamicin	Tobram ycin	Levofloxadn	Tetracycline	Minocycline	Trimethoprim-sulfamethoxazole	Nitrofurantoin§	Oral Cephalosporins for UTI§
	_			_			Ente	robact	eriacea	e											
Citrobacter freundii	54	R	R	76	75	74	91	R	R	96	98	87	100	94	91	96	85	-	78	100 (21)+	R
Enterobacter (Klebsiella) aerogenes	68	R	R	82	81	82	97	R	R	97	96	79	100	100	100	99	93	-	100	9 (23)+	R
Enterobacter cloacae	199	R	R	80	79	80	92	R	R	87	99	83	100	94	93	95	89	-	88	32 (41)	R
Escherichia coli	1318	42	46	91	94	88	90	92	63	99	100	95	100	89	88	70	72	-	68	97 (861)	85 (861
Klebsiella pneumoniae	403	R	81	97	96	94	96	88	84	97	99	93	100	98	97	98	84	-	94	38 (174)	92 (177
Klebsiella oxytoca	91	R	56	95	98	95	100	98	36	100	100	93	100	97	97	99	97	1	96	90 (31)	81 (31)
Morganella morganii	51	R	14	96	78	80	100	R	R	98	100	100	100	76	82	75	R	R	69	R	R
Proteus mirabilis	137	85	91	99	99	96	98	96	R	99	100	100	100	85	84	72	R	R	76	R	R
Serratia marcescens	131	R	R	99	100	93	99	R	R	98	99	95	100	98	77	99	0	-	100	R	R
Acinetobacter baumannii+	24	R	57	R	39	Non 30	-ferme 43	nting G R	R	egative R	s 54	-	52	43	52	46	42	-	58	-	R
Acinetobacter Iwoffii	1	R	-	R	-		-	R	R	R	-		-				(19)+				R
Burkholderia cepacia complex	9	R	R	<u> </u>	-	R	-	R	R	R	-	R	R	R	R	-	-	-	-	-	R
Pseudomonas aeruginosa	426	R	R	68	82	R	75	R	R	R	77	77	90	87	89	68	R	R	R		R
Pseudomonas aeruginosa (Non-CF isolates)	362	R	R	69	84	R	81	R	R	R	81	77	99	88	91	74	R	R	R	-	R
Pseudomonas aeruginosa (CF isolates)	64	R	R	64	71	R	44	R	R	R	55	75 (16)+	38	67 (15)+	83	31	R	R	R	-	R
Stenotrophomonas maltophila	74	R	R	-	••	R	-	R	R	R	-	R	R	R	R	78	R	99	99	-	R
						-	Other	Gram-	negativ	/es		-									
Haemophilus influenzae	131	90 (84)	-	-	-	100	-	-	-	-	-	-	-	-	-	100	99	-	64	-	-

Chandler Medical Center (Including Emergency Department)

*The percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient. Organisms with < 15 isolates do not have sensitivities reported due to lack of scientific validity.

+Calculated from fewer than the standard recommendation of 30 isolates; number in parentheses is number of isolates tested


§Data from urinary isolates only

Abbreviations: CF - cystic fibrosis; R - intrinsic resistance; [-] Drug not tested or not indicated

**Selective isolates (ex. multi-drug resistant organisms) were tested but did not achieve threshold for reporting

It's All About Odds – what is the most likely organism? And what is the chance of resistance?

Who is this Greek god? Hint: look at the staff






28yo student w/o PMH, presents with fever, productive cough, and feeling unwell. CXR shows RLL infiltrate. What treatment is most appropriate?

- A. Admit for IV Levofloxacin
- B. Admit for Vancomycin & Pip/tazo
- C. Outpatient Levofloxacin
- D. Outpatient Azithromycin
- E. Admit for IV Ceftriaxone/Azithro

CAP: What Are We Covering?

Most Common Causes of CAP in this previously healthy patient?:


- Typical
 - Strep Pneumoniae
- Atypical
 - Mycoplasma
 - Chlamydophila



To Admit or Not Admit?

• Admit:

- CURB-65 >=2 or CRB-65 >/= 1
- New hypoxia
- Inability to take PO
- Failure of outpatient therapy



CLASSIC REPRINT SERIES

52yo man with DM & COPD, presents with fever, productive cough, and feeling unwell. CXR shows RLL infiltrate. <u>What Treatment is most appropriate?</u>

- A. Admit for IV Levofloxacin
- B. Admit for Vancomycin & Pip/tazo
- C. Outpatient Levofloxacin
- D. Outpatient Azithromycin
- E. Admit for IV Ceftriaxone/Azithro

Pneumonia: What are we covering?

Common Things:


• Strep Pneumo & Atypical

Underlying lung disease – increases risk for Gram (-)'s

- H. Influenzae
- Moraxella
- O Legionella
- Pseudomonas

Diabetes:

O Increases risk for drug resistant strep pneumo





- Healthy patient w/ CAP:
 - Atypical, strep pneumoniae
- Underlying lung disease
 - Gram negatives, legionella
- Comorbid conditions or recent Abx:
 - Drug resistant strep pneumo
- Post-Flu, nursing homes, recent hospitalization, cavitary PNA:
 - MRSA

Table 8. Epidemiologic conditions and/or risk factors related to specific pathogens in community-acquired pneumonia.

Condition	Commonly encountered pathogen(s)
Alcoholism	Streptococcus pneumoniae, oral anaerobes, Klebsiella pneumoniae, Acinetobacter species, Mycobacterium tuberculosis
COPD and/or smoking	Haemophilus influenzae, Pseudomonas aeruginosa, Legionella species, S. pneumoniae, Moraxella carar- rhalis, Chlamydophila pneumoniae
Aspiration	Gram-negative enteric pathogens, oral anaerobes
Lung abscess	CA-MRSA, oral anaerobes, endemic fungal pneumonia, M. tuberculosis, atypical mycobacteria
Exposure to bat or bird droppings	Histoplasma capsulatum
Exposure to birds	Chlamydophila psittaci (if poultry: avian influenza)
Exposure to rabbits	Francisella tularensis
Exposure to farm animals or parturient cats	Coxiella burnetti (Q fever)
HIV infection (early)	S. pneumoniae, H. influenzae, M. tuberculosis
HIV infection (late)	The pathogens listed for early infection plus Pneumocys- tis jirovecii, Cryptococcus, Histoplasma, Aspergillus, atypical mycobacteria (especially Mycobacterium kansasii), P. aeruginosa, H. influenzae
Hotel or cruise ship stay in previous 2 weeks	Legionella species
Travel to or residence in southwestern United States	Coccidioides species, Hantavirus
Travel to or residence in Southeast and East Asia	Burkholderia pseudomallei, avian influenza, SARS
Influenza active in community	Influenza, S. pneumoniae, Staphylococcus aureus, H. influenzae
Cough >2 weeks with whoop or posttussive vomiting	Bordetella pertussis
Structural lung disease (e.g., bronchiectasis)	Pseudomonas aeruginosa, Burkholderia cepacia, S. aureu
Injection drug use	S. aureus, anaerobes, M. tuberculosis, S. pneumoniae
Endobronchial obstruction	Anaerobes, S. pneumoniae, H. influenzae, S. aureus
In context of bioterrorism	Bacillus anthracis (anthrax), Yersinia pestis (plague), Francisella tularensis (tularemia)

22yo student, presents with fever, headache, nausea, neck stiffness.

What are your antibiotics of choice?

- A. IV Ceftriaxone
- B. IV Vancomycin
- C. IV Vanc + Ceftriaxone
- D. IV Vanc + Ceftriaxone + Ampicillin


Bacterial Meningitis: What are we Covering?

Community Acquired Meningitis:

- N. Meningitis
- Strep Pneumo
- Together account for > 80%

But why vancomycin?

• Drug resistant strep pneumo



55yo lady, presents with fever, headache, nausea, neck stiffness.

What are your antibiotics of choice?

- A. IV Ceftriaxone
- B. IV Vancomycin
- C. IV Vanc + Ceftriaxone
- D. IV Vanc + Ceftriaxone + Ampicillin

Bacterial Meningitis: What are we covering?

Common:

- O Strep. Pneumo
- 0 N. meningitides

Why ampicillin?

- O Listeria
- Who?
 - > 50

• Altered cell mediated immunity: HIV, immunosuppressants

Bacterial Meningitis: Special Considerations

Hospital Acquired or Neurosurgical Procedures:

- o MRSA
- Pseudomonas
- Gram negatives

Regimen:

- MRSA: vancomycin
- Gram (-)/Pseudomonas: cefepime/ceftazidime or meropenem

Table 4. Recommendations for empirical antimicrobial therapy for purulent meningitis based on patient age and specific predisposing condition (A-III).

Predisposing factor	Common bacterial pathogens	Antimicrobial therapy						
lge								
2–50 years	N . meningitidis, S. pneumoniae	Vancomycin plus a third-generation cephalosporin ^{a,b}						
>50 years	S. pneumoniae, N. meningitidis, L. monocytogenes, aerobic gram-negative bacilli	Vancomycin plus ampicillin plus a third-generation cephalosporin ^{a,b}						
lead trauma								
Basilar skull fracture	S. pneumoniae, H. influenzae, group A β-hemolytic streptococci	Vancomycin plus a third-generation cephalosporin ^a						
Penetrating trauma	Staphylococcus aureus, coagulase-negative staphylo- cocci (especially Staphylococcus epidermidis), aer- obic gram-negative bacilli (including Pseudomonas aeruginosa)	Vancomycin plus cefepime, vancomycin plus ceftazi- dime, or vancomycin plus meropenem						
Postneurosurgery	Aerobic gram-negative bacilli (including <i>P. aeruginosa</i>), <i>S</i> . aureus, coagulase-negative staphylococci (es- pecially <i>S. epidermidis</i>)	Vancomycin plus cefepime, vancomycin plus ceftazi- dime, or vancomycin plus meropenem						
CSF shunt	Coagulase-negative staphylococci (especially <i>S. epi- dermidis</i>), <i>S. aureus</i> , aerobic gram-negative bacilli (including <i>P. aeruginosa</i>), <i>Propionibacterium acnes</i>	Vancomycin plus cefepime, ^e vancomycin plus ceftaz dime, ^e or vancomycin plus meropenem ^e						

Suspicion for bacterial meningitis

Yes

Immunocompromise, history of CNS disease, new onset seizure, papilledema, altered consciousness, or focal neurologic deficit;^a or delay in performance of diagnostic lumbar puncture

No Blood cultures and lumbar puncture STAT ↓ Dexamethasone^b + empirical antimicrobial therapy^{c,e} Yes

Perform lumbar puncture

ImbarBlood cultures STATImpiricalImpirical $py^{c,e}$ Dexamethasone^b + empirical
antimicrobial therapy^cImpiricalImpirical
Antimicrobial therapy^c</

CSF findings c/w bacterial meningitis

Yes

No

Yes


Dexamethasone^b + empirical antimicrobial therapy^c Dexamethasone^b + targeted antimicrobial therapy^d A 34 y/O M presents with pain, swelling and erythema over his left thigh. On exam there is a 3cm area of fluctuance with 6cm or overlying erythema.

In addition to I&D, which is the most treatment?

A.Cephalexin B.Bactrim

C.Levaquin

D.Dicloxacillin



Cellulitis: What are we Covering?

- Most Common Pathogens?
 - O Staph
 - O Strep
- Purulent:
 - O MSSA/MRSA

Special MRSA considerations for non-purulent infections:

• Penetrating trauma, IVDU, h/o or current MRSA infection, sepsis



Cellulitis Therapies: (2014 IDSA SSTI Guidelines)

Strep/MSSA – First Line:

O PO ?: dicloxacillin, cephalexin, amoxicillin-clavulanate, macrolide
O IV ?: penicillin, cefazolin, ceftriaxone

MRSA Coverage – Consider if purulence/abscess or risk factors:
 PO?: doxycycline, Bactrim, clindamycin, linezolid
 IV?: daptomycin, vancomycin, ceftaroline

Skin & Soft Tissue Special Circumstances:

Bite wound:

• Think Anaerobes: Tx with augmentin or clindamycin

Diabetic Foot Infection:

Often polymicrobial including gram negatives (incl pseudomonas) and anaerobes
 Tx: augmentin, Levaquin, clindamycin, doxycycline, zosyn, vancomycin, linezolid
 Oconsider adding MRSA coverage for purulence/risk factors

27 YO WOMAN WITH DYSURIA, HEMATURIA, AND INCREASED URINARY FREQUENCY PRESENTS TO CLINIC. SHE IS HEMODYNAMICALLY STABLE AND TOLERATING PO.

WHAT ANTIBIOTIC IS MOST APPROPRIATE?

- A. Nitrofurantion
- B. Ciprofloxacin
- C. Ceftriaxone
- D. Zosyn

Urinary Tract Infections:

What are we covering?

- Most common
 - E. Coli
 - Klebsiella

O Other: Enterococcus; Proteus, Pseudomonas, staph saprophyticus

UTI's Treatment (IDSA)

Uncomplicated Cystitis:

O PO: Bactrim, Nitrofurantoin (fosfomycin, beta lactams)O IV: Rocephin, unasyn

Pyelonephritis:

• PO: Levaquin, Bactrim if susceptible

○ IV: Rocephin

UTI: special points

Enterococcal UTI:

• No cephalosporins

O Ampicillin, Fosfomycin, Vanc or Dapto

Chandler E. Coli Strains have high fluoroquinolone resistance

Cannot use nitrofurantoin for pyelonephritis

Only Tx asymptomatic bacteriuria in:

• Pregnancy & Upcoming GU surgery

